However, early results from the phase 3 randomized clinical trial in TP53-mutated MDS failed to meet the primary end point of CR rate (33.3% in eprenetapopt + azacitidine, 22.4% in azacitidine alone, P = 0.13; www.aprea.com). Here, TP53 is linked to myelodysplastic syndrome.